Peptide Schedule
Liraglutide31 residuesHAEGTFTSDVSSYLEGQAAKEFIAWLVKGRGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Liraglutide Dosage Calculator
Liraglutide is a GLP-1 receptor agonist that's been on the market longer than most people realize — FDA-approved as Victoza for type 2 diabetes back in 2010, then as Saxenda for chronic weight management in 2014.
600mcg · Daily
Summary: Add 0mL BAC water to your 18mg vial. Draw to < 0.1 units on a U-100 syringe for a 600mcg dose. This vial will last 0 doses.
Cycle Planner
Liraglutide Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~13 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Liraglutide Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 600mcg | Daily |
| Moderate | 1,800mcg | Daily |
| Aggressive | 3mg | Daily |
Note: Pre-filled pen — no reconstitution needed. Titrate up by 600mcg each week to minimize nausea. Saxenda tops out at 3mg/day for weight loss; Victoza caps at 1.8mg/day for diabetes.
About Liraglutide
Liraglutide is a GLP-1 receptor agonist that's been on the market longer than most people realize — FDA-approved as Victoza for type 2 diabetes back in 2010, then as Saxenda for chronic weight management in 2014. It's a modified version of human GLP-1 with a fatty acid side chain that lets it bind to albumin in the blood, extending its half-life from minutes to about 13 hours. That's long enough for once-daily dosing but short enough that side effects clear faster than weekly options like semaglutide if you don't tolerate it well. The LEADER trial, which enrolled over 9,300 patients with type 2 diabetes and high cardiovascular risk, showed liraglutide reduced major cardiovascular events by 13% compared to placebo. That was a big deal — it made Victoza one of the first diabetes drugs proven to protect the heart, not just lower blood sugar. On the weight loss side, the SCALE-Obesity and Prediabetes trial demonstrated an average loss of about 8% of body weight at the 3mg dose over 56 weeks. Not as dramatic as semaglutide's numbers, but still clinically meaningful. Saxenda comes as an 18mg pre-filled pen that delivers doses from 0.6mg to 3mg. You start low and titrate up weekly — 0.6mg the first week, 1.2mg the second, and so on until you hit the target dose. This slow ramp matters because GI side effects (especially nausea) are the most common reason people quit. Most find the nausea fades after 2-3 weeks at each dose level. One practical advantage of liraglutide over newer weekly GLP-1s: if you get hit hard by side effects, they clear out in about a day since the drug's half-life is only 13 hours. With semaglutide, you're stuck waiting a week. That makes liraglutide a reasonable starting point for people who are nervous about GLP-1 therapy or have a history of GI sensitivity.